全文获取类型
收费全文 | 3261篇 |
免费 | 216篇 |
国内免费 | 103篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 21篇 |
妇产科学 | 16篇 |
基础医学 | 128篇 |
口腔科学 | 49篇 |
临床医学 | 212篇 |
内科学 | 138篇 |
皮肤病学 | 19篇 |
神经病学 | 36篇 |
特种医学 | 109篇 |
外科学 | 88篇 |
综合类 | 556篇 |
预防医学 | 262篇 |
眼科学 | 12篇 |
药学 | 945篇 |
4篇 | |
中国医学 | 811篇 |
肿瘤学 | 158篇 |
出版年
2024年 | 28篇 |
2023年 | 71篇 |
2022年 | 140篇 |
2021年 | 168篇 |
2020年 | 164篇 |
2019年 | 113篇 |
2018年 | 109篇 |
2017年 | 100篇 |
2016年 | 114篇 |
2015年 | 94篇 |
2014年 | 223篇 |
2013年 | 199篇 |
2012年 | 204篇 |
2011年 | 235篇 |
2010年 | 182篇 |
2009年 | 162篇 |
2008年 | 167篇 |
2007年 | 158篇 |
2006年 | 93篇 |
2005年 | 139篇 |
2004年 | 98篇 |
2003年 | 87篇 |
2002年 | 44篇 |
2001年 | 63篇 |
2000年 | 45篇 |
1999年 | 50篇 |
1998年 | 59篇 |
1997年 | 30篇 |
1996年 | 38篇 |
1995年 | 34篇 |
1994年 | 31篇 |
1993年 | 25篇 |
1992年 | 14篇 |
1991年 | 5篇 |
1990年 | 11篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 9篇 |
1981年 | 7篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1974年 | 2篇 |
1972年 | 2篇 |
排序方式: 共有3580条查询结果,搜索用时 15 毫秒
131.
Sacha P. Broccard Ali Abbaszadeh Kasbi Sanjay P. Bagaria Jeremy Jones Mira Shoudry Emmanuel M. Gabriel 《Journal of gastrointestinal oncology.》2022,13(1):438
ObjectiveIn this review, we summarize ongoing clinical trials involving liquid biopsies (LB) for colorectal cancer (CRC), outlining the current landscape and the future implementation of this technology. We also describe the current use of LB in CRC treatment at our institution, the Mayo Clinic Enterprise.BackgroundThe use of LB in CRC treatment merits close attention. Their role is being evaluated in the screening, non-intervention, intervention, and surveillance settings through many active trials. This, coupled with the technique’s rapid integration into clinical practice, creates constant evolution of care.MethodsReview of ClinicalTrials.gov was performed identifying relevant and active trials involving LB for CRC. “Colorectal cancer” plus other terms including “liquid biopsies” and “ctDNA” were used as search terms, identifying 35 active trials.ConclusionsLB use for the CRC is actively being investigated and requires close attention. Based on current evidence, Mayo Clinic Enterprise currently uses LB in the non-interventional, interventional and surveillance setting, but not for screening. Results of these trials may further establish the use of LB in the management of CRC. 相似文献
132.
134.
在《新型冠状病毒肺炎诊疗方案(试行第六版)》中推荐的清肺排毒汤,临床观察疗效显著。笔者拟探讨新型冠状病毒肺炎(COVID-19)的寒疫病机以及清肺排毒汤的方药组成机制,认为该方能疏解表里、通调三焦,具有宣肺行气、透邪解毒、润燥化湿、逐水泻热的功效,切合COVID-19寒、燥、湿的病机特点,且能有效的针对症状进行治疗,应推广全国各地广泛使用以遏制疫情蔓延。 相似文献
135.
目的探究清肺化浊汤联合胸腺五肽治疗恶性肿瘤合并肺部感染的临床效果和对淋巴细胞亚群水平影响。方法选取恶性肿瘤合并肺部感染的患者109例作为研究对象,按随机数字表法将其分为两组,对照组54例患者采用胸腺五肽进行治疗,观察组55例患者在观察组的基础上予以清肺化浊汤辅助治疗。观察比较两组治疗前后临床症状改善情况、炎症指标和T淋巴细胞亚群水平变化情况。结果观察组胸部X线好转时间、退热时间、咳痰咳嗽好转时间明显优于对照组(P<0.05);观察组炎症因子水平、CD3^+(71.08±3.86)%、CD4^+(41.17±3.21)%、CD4^+CD25^+(1.52±0.37)%和CD3^+CD+8(25.17±2.56)%水平明显优于对照组炎症因子水平、CD3^+(64.31±4.17)%、CD4^+(34.24±2.53)%、CD4^+CD25^+(2.11±0.45)%和CD3^+CD+8(27.84±2.15)%,差异具有统计学意义(P<0.05)。结论清肺化浊汤联合胸腺五肽治疗恶性肿瘤合并肺部感染患者效果明显,可以有效改善患者的临床症状,降低炎症因子水平,增强患者的免疫功能,值得临床推广应用。 相似文献
136.
目的观察养阴清肺汤治疗急性放射性口腔炎的临床疗效及其对患者免疫功能和炎症细胞因子的影响。方法患者100例,按照随机数字表法分为治疗组与对照组各50例,两组均采用西医常规治疗,治疗组在对照组治疗基础上加用养阴清肺汤,两组疗程均持续到放疗结束后2~4周。观察两组临床疗效,治疗前后两组唾液中γ-干扰素(IFN-γ)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及白细胞介素-8(IL-8)水平及两组治疗前后免疫功能指标(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)的变化情况。结果治疗组总有效率为92.00%,显著高于对照组的76.00%(P<0.05)。治疗组症状体征、唾液炎症细胞因子、相关免疫功能指标恢复程度均优于对照组(P<0.05)。结论养阴清肺汤可有效缓解急性放射性口腔炎的疼痛和黏膜损伤程度,加速患者伤口愈合,有效抑制急性放射性口腔炎的相关炎症细胞因子。 相似文献
137.
138.
139.
140.
《Clinical lung cancer》2020,21(6):545-552.e1
BackgroundOutcomes of therapy targeting molecular driver alterations detected in advanced non–small-cell lung (NSCLC) using circulating tumor DNA (ctDNA) have not been widely reported in patients who are targeted therapy-naive.Patients and MethodsWe performed a multicenter retrospective review of patients with unresectable stage IIIB to IV NSCLC who received matched therapy after a targetable driver alteration was identified using a commercial ctDNA assay through usual clinical care. Eligible patients must not have received targeted therapy prior to ctDNA testing (prior chemotherapy or immunotherapy was permitted). Kaplan-Meier analysis was used to estimate the median duration of targeted therapy. Patients still on targeted therapy were censored at last follow-up.ResultsSeventy-six patients met inclusion criteria. The median age of diagnosis of NSCLC was 64.5 years (range, 31-87 years), 67% were female, 74% were never-smokers, and 97% had adenocarcinoma histology. Twenty-one (28%) patients received systemic treatment prior to targeted therapy, including chemotherapy (n = 17), immunotherapy (n = 5), and/or a biologic (n = 4). Thirty-three (43%) patients remain on targeted therapy at the time of data analysis. The median time on targeted therapy was similar to what has been reported for tissue-detected oncogenic driver mutations in the targeted therapy-naive setting.ConclusionsPatients with ctDNA-detected drivers had durable time on targeted therapy. These treatment outcomes data compliment previous studies that have shown enhanced targetable biomarker discovery rates and high tissue concordance of ctDNA testing when incorporated at initial diagnosis of NSCLC. Identification of NSCLC driver mutations using well-validated ctDNA assays can be used for clinical decision-making and targeted therapy assignment. 相似文献